Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K, et al. In Vivo. 2019 Sep-Oct.
Show full citation
Abstract.
BACKGROUND/AIM:
Trabectedin is a synthetic antineoplastic agent approved for advanced soft tissue sarcoma (STS) in Japan. The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS.
PATIENTS AND METHODS:
We retrospectively reviewed 38 patients with advanced STS who received salvage chemotherapy with trabectedin.
RESULTS:
The overall response and disease control rates were 16% (5 patients) and 67% (20 patients), respectively. The median progression-free and overall survival were 7.3 and 17.8 months, respectively. There were no significant differences between patients with liposarcoma or leiomyosarcoma and those without, or between patients with TRS and those without. The most common grade 3-4 AEs were elevated transaminases and neutropenia.
CONCLUSION:
Trabectedin 1.2 mg/m2, as the approved dose in Japan, showed similar efficacy to the dose of 1.5 mg/m2 used in Western countries. Trabectedin could be an option for advanced STS in Japan, regardless of histological subtype.
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
